Preload Reduction Medications
Loop diuretics are the first-line agents for preload reduction in heart failure, with furosemide 20-40 mg IV (or oral equivalent) as the initial dose for diuretic-naive patients, or at least equivalent to the current oral dose for those already on diuretics 1.
First-Line Venodilators
For acute heart failure with systolic blood pressure >90 mmHg, IV vasodilators should be considered for symptomatic relief and are particularly valuable in hypertensive acute heart failure as initial therapy 2. The primary venodilators include:
Nitroglycerin
- Mechanism: Predominantly venodilator at lower doses, reducing preload through direct venous smooth muscle relaxation
- Advantage: May dilate coronary arteries at higher doses, beneficial in ischemic presentations
- Limitation: Tachyphylaxis develops, requiring dose escalation
- Side effects: Hypotension and headache 3
Nitroprusside
- Mechanism: Balanced arterial and venous vasodilator
- Advantage: Very short half-life allows rapid titration
- Caution: Risk of cyanide/thiocyanate toxicity with prolonged use (>24 hours), especially with renal insufficiency 3
Nesiritide
- Mechanism: Recombinant B-type natriuretic peptide causing venous and arterial vasodilation
- Advantage: May potentiate diuretic effects
- Concern: Meta-analyses suggest potential worsening of renal function and decreased 30-day survival compared to conventional therapies 3
First-Line Diuretics: Dosing Regimens
Loop diuretics are preferred over thiazides for most heart failure patients 1. The 2022 ACC/AHA/HFSA guidelines provide specific dosing:
Loop Diuretics (First-Line)
| Drug | Initial Daily Dose | Maximum Total Daily Dose | Duration of Action |
|---|---|---|---|
| Furosemide | 20-40 mg once or twice | 600 mg | 6-8 hours |
| Torsemide | 10-20 mg once | 200 mg | 12-16 hours |
| Bumetanide | 0.5-1.0 mg once or twice | 10 mg | 4-6 hours |
Torsemide and bumetanide may be superior to furosemide due to increased oral bioavailability 1.
Administration Strategy
- Give as intermittent boluses or continuous infusion, adjusting dose and duration based on symptoms and clinical status 2
- Target weight loss: 0.5-1.0 kg daily in outpatients 1
- Monitor: Symptoms, urine output, renal function, and electrolytes regularly 2
Combination Therapy for Diuretic Resistance
When loop diuretics alone are insufficient:
Add thiazide-type diuretic (metolazone 2.5 mg once daily, maximum 20 mg) or spironolactone to loop diuretics for refractory edema 1, 2.
Thiazide Diuretics (Second-Line/Combination)
| Drug | Initial Daily Dose | Maximum Total Daily Dose |
|---|---|---|
| Metolazone | 2.5 mg once | 20 mg |
| Chlorothiazide | 250-500 mg once or twice | 1000 mg |
| Hydrochlorothiazide | 25 mg once or twice | 200 mg |
Critical Clinical Considerations
Comparative Hemodynamics
Nitroprusside is superior to furosemide for immediate treatment of acute left ventricular failure: In direct comparison, nitroprusside reduced pulmonary wedge pressure from 30.5 to 15.9 mmHg while increasing cardiac index from 2.33 to 3.62 L/min/m², whereas furosemide only modestly reduced wedge pressure to 27.5 mmHg without improving cardiac output 4. This demonstrates that nitroprusside provides both preload AND afterload reduction with improved ventricular performance, while furosemide provides only preload reduction 4.
Common Pitfall: Early Furosemide Response
IV furosemide causes an initial paradoxical rise in pulmonary capillary wedge pressure for the first 15 minutes before diuresis-induced reduction occurs 5. This is due to release of endogenous vasoconstrictors. This deleterious early effect can be blocked by combined preload and afterload reduction 5.
Diuretic Resistance Management
Overcome resistance through:
- Escalating loop diuretic dose
- Switching to IV administration (bolus or continuous infusion)
- Combining different diuretic classes 1
Avoid NSAIDs and excessive dietary sodium, which block diuretic effects 1.
Maintenance Therapy
In any patient with history of congestion, maintenance diuretics should be continued to prevent recurrent symptoms, using the lowest dose to maintain euvolemia 1. However, diuretics should never be used in isolation but always combined with guideline-directed medical therapy (GDMT) that reduces hospitalizations and mortality 1.